BDTX · Black Diamond Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $33.56M | $51.31M | $59.35M | $64.44M | $96.83M | $48.21M |
| SG&A | $16.57M | $27.47M | $27.11M | $28.39M | $30.04M | $21.36M |
| Total Operating Expenses | $57.48M | $78.78M | $86.46M | $92.83M | $126.87M | $69.57M |
| D&A | $325.0K | $343.0K | $437.0K | $508.0K | $205.0K | $52.0K |
| Operating Income | $12.52M | ($78.78M) | ($86.46M) | ($92.83M) | ($126.87M) | ($69.57M) |
| Interest Expense | - | - | - | - | $0 | $1.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $22.37M | ($69.68M) | ($82.44M) | ($91.17M) | ($125.60M) | ($67.25M) |
| EPS - Basic | $0.39 | ($1.27) | ($1.88) | ($2.52) | ($2.05) | - |
| EPS - Diluted | $0.39 | ($1.27) | ($1.88) | ($2.52) | ($2.05) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.99M | $36.44M | $56.22M | $34.31M | $65.80M | $34.60M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $579.0K | $4.01M | $2.32M | $1.88M | $4.11M | $2.54M |
| Current Assets | $132.44M | $101.18M | $134.03M | $127.71M | $215.70M | $319.55M |
| Total Assets | $143.01M | $122.64M | $158.57M | $156.25M | $247.68M | $329.67M |
| Current Liabilities | $15.73M | $20.57M | $19.65M | $15.26M | $23.64M | $14.22M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $30.80M | $39.35M | $41.83M | $40.56M | $51.78M | $21.91M |
| Stockholders' Equity | $112.21M | $83.28M | $116.74M | $115.69M | $195.90M | $307.76M |
| Retained Earnings | ($464.74M) | ($487.11M) | ($417.43M) | ($334.99M) | ($243.82M) | ($118.22M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $29.61M | ($62.30M) | ($66.72M) | ($85.08M) | ($100.15M) | ($52.15M) |
| Investing Cash Flow | ($44.91M) | $16.97M | $16.35M | $53.37M | $130.61M | ($281.69M) |
| Financing Cash Flow | ($146.0K) | $25.55M | $71.93M | $177.0K | $729.0K | $214.94M |
| CapEx | - | $0 | $33.0K | $192.0K | $2.71M | $142.0K |
| Free Cash Flow | - | ($62.30M) | ($66.75M) | ($85.27M) | ($102.86M) | ($52.29M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | 0.89 | 0.81 | 0.94 | 0.82 | 0.78 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | 0.0% | - | - | - | - | - |
| Return on assets | 15.6% | -56.8% | -52.0% | -58.3% | -50.7% | -20.4% |
| Return on equity | 19.9% | -83.7% | -70.6% | -78.8% | -64.1% | -21.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 8.42 | 4.92 | 6.82 | 8.37 | 9.12 | 22.48 |
| Quick ratio | 8.42 | 4.92 | 6.82 | 8.37 | 9.12 | 22.48 |
| Cash ratio | 1.33 | 1.77 | 2.86 | 2.25 | 2.78 | 2.43 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -69570.0x |
| Equity multiplier | 1.27 | 1.47 | 1.36 | 1.35 | 1.26 | 1.07 |
| Liabilities / Assets | 0.22 | 0.32 | 0.26 | 0.26 | 0.21 | 0.07 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 6.2x | - | - | - | - | - |
| P / B | 1.2x | 1.4x | 1.1x | 0.6x | 0.9x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | 9.3x | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 8.9% | 6.9% | 26.8% | -82.4% | -681.3% |
| Net income growth (YoY) | - | 15.5% | 9.6% | 27.4% | -86.7% | -653.0% |
| EPS growth (YoY) | - | 32.4% | 25.4% | -22.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 6.7% | 21.7% | 17.1% | -96.7% | -513.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 34.7% | -28.7% | 0.9% | -40.9% | -36.3% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Black Diamond Therapeutics against the 5 most active filers in the same SIC group.